https://www.selleckchem.com/pr....oducts/nedisertib.ht
5-17). Patients undergoing sRS-RARP had better immediate (25.0% vs 0.0%, P .001), 3 month (80.0% vs 0%, P .001), and 12 month continence rates (100% vs 44%, P=.0384) compared to sRARP patients. Likewise, median time to continence was significantly shorter for sRS-RARP patients (90.0 vs 270.0 days, P=.0095). Biochemical recurrence rate was 20.0% in the sRS-RARP group and 33.3% in the sRARP group (P=.6. Early experience suggests that sRS-RARP is feasible, oncologically safe, and may offer improved continence compared to the
Like
Comment
Share
